Breast cancer treatment in early-stage disease
The sponsor supports clinical research in early invasive triple-negative breast cancer with homologous recombination deficiency and in endocrine-responsive HER2-negative breast cancer, with a focus on pre-operative treatment strategies and surgical outcome assessment.
- Triple-negative breast cancer
- Homologous recombination deficiency
- HER2-negative early breast cancer
- Endocrine-responsive disease
Research activity in this area includes approaches aimed at improving response before surgery and refining treatment selection for biologically defined breast cancer subtypes.
Targeted therapy and DNA repair-directed oncology
Clinical research includes combinations involving olaparib and carboplatin in HRD-positive breast cancer, reflecting interest in therapies that exploit defects in DNA repair pathways.
- Olaparib
- Carboplatin
- Homologous recombination deficiency
- Neoadjuvant oncology
This work centers on biomarker-defined disease and treatment strategies linked to molecular vulnerability in breast tumors.
Cancer prevention in hereditary breast cancer
The sponsor funds prevention-focused research in women carrying a BRCA1 germline mutation, with attention to reducing the occurrence of invasive breast cancer and ductal carcinoma in situ.
- BRCA1 mutation
- Breast cancer prevention
- Hereditary cancer risk
- Denosumab
Its prevention portfolio is directed toward women at elevated inherited risk of breast malignancy.
Endocrine therapy and cell-cycle inhibition
Another area of interest is combination treatment with elacestrant, ribociclib, and aromatase inhibitor-based therapy in hormone receptor–responsive early breast cancer, including use in pre-/perimenopausal women and men with GnRH agonist support where relevant.
- Elacestrant
- Ribociclib
- Aromatase inhibitor therapy
- Hormone receptor–responsive breast cancer
These studies address endocrine-sensitive disease biology and the integration of targeted agents in early breast cancer management.
